Blinatumomab
Multispecific antibody
Evidence outlook
Approved: Acute Lymphoblastic Leukemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Rheumatoid Arthritis · Phase 2Systemic Lupus Erythematosus · Phase 2
Also approved (4)
- MRD-positive B-cell Precursor ALL BLINCYTO is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adult and pediatric patients one month and older.
- Relapsed or Refractory B-cell Precursor ALL BLINCYTO is indicated for the treatment of relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older.
- Relapsed or refractory B-cell acute lymphoblastic leukemia
- CD19 positive relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in adults (Blincyto; conditional marketing authorisation)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03476239 NCT03476239 · Acute Lymphoblastic Leukemia Participants received open-label blinatumomab without randomization or a comparator arm, so the reported 48.3% CR/CRh* response rate cannot establish how much benefit was caused by treatment versus the underlying patient population or other factors. The primary endpoint was a clinically meaningful leukemia response measure, but this uncontrolled design provides limited evidence. Registry: NCT03476239 | 3 | Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2 Treatment Cycles With Blinatumomab (Within 2 cycles of treatment (12 weeks)) 2019-08-21 | Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2 Treatment Cycles With Blinatumomab (Within 2 cycles of treatment (12 weeks)): Blinatumomab — Interim Analysis: 45.6 percentage of participants (95% CI 35 to 56.4); Final Analysis: 48.3 percentage of participants (95% CI 39.1 to 57.6) | Weak signal | link ↗ |
View 7 more trials
NCT02393859 NCT02393859 · Leukemia, Acute Lymphoblastic The trial randomly assigned 111 participants to blinatumomab or active standard chemotherapy, and its primary endpoint was the hard clinical outcome of event-free survival. The primary endpoint was met in favor of blinatumomab (p<0.001), but treatment assignment was not blinded, so the evidence is considered moderate rather than strong. Registry: NCT02393859 | 3 | Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis) (As of the primary analysis data cutoff date (17 July 2019), overall median follow-up time for EFS was 22.4 months.); Kaplan Meier Estimate: EFS (Final Analysis) (At final analysis, overall median follow-up time for EFS was 51.9 months.) 2019-07-17 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
BLAST NCT01207388 · Acute Lymphoblastic Leukemia Registry: NCT01207388 | 2 | Percentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle (During the first cycle (6 weeks)) 2014-02 | Percentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle (During the first cycle (6 weeks)): Blinatumomab 77 percentage of participants (95% CI 68.1 to 84.4) | not yet graded | link ↗ |
NCT02013167 NCT02013167 · Acute Lymphoblastic Leukemia Registry: NCT02013167 | 3 | Overall Survival (From randomization until the data cut-off date of 04 January 2016; median observation time was 11.8 months in the SOC group and 11.7 months in the blinatumomab group.) 2015-12-29 | Overall Survival (From randomization until the data cut-off date of 04 January 2016; median observation time was 11.8 months in the SOC group and 11.7 months in the blinatumomab group.): Standard of Care Chemotherapy 4 months (95% CI 2.9 to 5.3) | Blinatumomab 7.7 months (95% CI 5.6 to 9.6) | not yet graded | link ↗ |
NCT01466179 NCT01466179 · Acute Lymphoblastic Leukemia Registry: NCT01466179 | 2 | Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment (Within the first 2 cycles of treatment, 12 weeks) 2013-10 | Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment (Within the first 2 cycles of treatment, 12 weeks): Blinatumomab 42.9 percentage of participants (95% CI 35.7 to 50.2) | not yet graded | link ↗ |
NCT02000427 NCT02000427 · Acute Lymphoblastic Leukemia Registry: NCT02000427 | 2 | Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles (Approximately 12 weeks, as of the data cut-off date of 20 May 2015) 2015-05-20 | Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles (Approximately 12 weeks, as of the data cut-off date of 20 May 2015): Blinatumomab 35.6 percentage of participants (95% CI 21.9 to 51.2) | not yet graded | link ↗ |
NCT01471782 NCT01471782 · Acute Lymphoblastic Leukemia Registry: NCT01471782 | 1/2 | Phase I: Number of Participants With Dose-limiting Toxicities (DLTs) (Cycle 1, 28 days); Percentage of Participants With Complete Remission in the First Two Cycles (Cycles 1 and 2 (12 weeks)) 2014-08 | Label-reported response: Twenty-three out of 70 (32.9%) patients achieved CR/CRh* within the first 2 treatment cycles with 17 out of 23 (73.9%) occurring within Cycle 1 of treatment. | not yet graded | link ↗ |
NCT02003222 NCT02003222 · Acute Lymphoblastic Leukemia Registry: NCT02003222 | 3 | Overall Survival (OS) Among Patients Who Were MRD Negative After Induction and Intensification Chemotherapy (Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years) 2023-06-23 | Results posted on ClinicalTrials.gov. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (78)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (19)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (29)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (3)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Phase 2/3 (2)
What this study did
What this study did
Competitive landscape
Other CD19 x CD3 drugs
Surovatamig, CLN-978, XmAb657. Compare all 4 CD19 x CD3 drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Acute Lymphoblastic Leukemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Blinatumomab: this drug | Approved | Multispecific antibody | CD19 x CD3 | Weak signal | NCT03476239: Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2 Treatment Cycles With Blinatumomab (Within 2 cycles of treatment (12 weeks)): Blinatumomab — Interim Analysis: 45.6 percentage of participants (95% CI 35 to 56.4); Final Analysis: 48.3 percentage of participants (95% CI 39.1 to 57.6) | |
| Methotrexate | Approved | Small molecule | Dihydrofolate reductase (DHFR), Folate Analog Metabolic Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Obecabtagene Autoleucel (Aucatzyl) | Approved | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Ponatinib (ICLUSIG) | Approved | Small molecule | BCR-ABL (including T315I) | Partial signal | Featured results are non-efficacy only in this race | |
| Revumenib | Approved | Small molecule | Menin | Weak signal | No reviewed efficacy summary in this indication | |
| Ziftomenib | Phase 1/2 | Small molecule | Menin | not yet graded | No reviewed efficacy summary in this indication | |
| XmAb657 | Phase 1(overall) | Multispecific antibody | CD19 x CD3 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(80 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Blinatumomab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
December 2026 (3)
What to watch
What to watch
What to watch
2027 (29)
January 2027 (1)
What to watch
February 2027 (4)
What to watch
What to watch
What to watch
What to watch
March 2027 (1)
What to watch
May 2027 (2)
June 2027 (2)
September 2027 (3)
What to watch
What to watch
What to watch
October 2027 (2)
November 2027 (3)
What to watch
What to watch
What to watch
December 2027 (11)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (21)
March 2028 (4)
What to watch
What to watch
What to watch
What to watch
April 2028 (1)
What to watch
May 2028 (3)
What to watch
What to watch
What to watch
June 2028 (2)
July 2028 (2)
August 2028 (1)
What to watch
October 2028 (1)
What to watch
November 2028 (2)
December 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (9)
January 2029 (1)
What to watch
February 2029 (1)
What to watch
July 2029 (1)
What to watch
August 2029 (2)
September 2029 (1)
What to watch
December 2029 (3)
What to watch
What to watch
What to watch
2030 (4)
April 2030 (1)
What to watch
July 2030 (1)
What to watch
October 2030 (1)
What to watch
December 2030 (1)
What to watch
2031 (7)
March 2031 (2)
April 2031 (1)
What to watch
June 2031 (1)
What to watch
September 2031 (2)
December 2031 (1)
What to watch
2032 (3)
March 2032 (2)
December 2032 (1)
What to watch
2033 (3)
March 2033 (1)
What to watch
June 2033 (1)
What to watch
September 2033 (1)
What to watch
2035 (1)
March 2035 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent